Dr. Taniguchi aimed to describe the pathomechanism of induction of severe airway symptoms in AERD patients and described potential mechanisms of anti-IgE (omalizumab) as a treatment for AERD.
Skin prick tests found that infants with eczema had significantly larger wheal sizes to histamine compared to infants without eczema.
They evaluated dupilumab’s effects on smell function with 60 patients with nasal polyps who were refractory to intranasal corticosteroids.
Allergen-specific subcutaneous immunotherapy (SCIT) reduced 5- to 11-year-old children’s need for inhaled corticosteroids (ICS) to manage asthma symptoms.
Assessment of predictive factors for systemic allergic reactions (SAR) determined that peanut oral immunotherapy (OIT) is safe in patients with peanut allergy (PA).
A total of 425 patients were included in both the modified intention-to-treat and safety analyses.
Supervised self-injection practice in the clinic to simulate adolescents’ use of an epinephrine autoinjector to manage food allergy anaphylaxis offers immediate improvements in patients’ comfort levels.
Adding tiotropium Respimat to maintenance therapy of inhaled corticosteroid was found to significantly improve lung function in adolescents and children.
Safety data of long-term treatment with 300IR 5-grass SL tablet indicated that “the most frequent ADRs, generally mild, were reported with decreasing incidences over the years studied and could persist up to 4 months during treatment.”
A Fluticasone Propionate Exhalation Delivery System (FLU-EDS) has shown significant improvements in patients diagnosed with Chronic Rhinosinusitis with Nasal Polyps.
